文献速递免疫规划慢病防控与筛查

2023-2024年度COVID-19疫苗对≥18岁终末期肾病患者COVID-19相关住院的保护效果——美国,2023年9月至2024年4月

Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged ≥18 years with end stage kidney disease - United States, September 2023-April 2024.
PubMed 文献 · Vaccine · 2025-04-03

美国采用医疗保险理赔记录对≥18岁接受透析的终末期肾病患者进行回顾性队列研究,评估2023-2024年度COVID-19疫苗效果。接种后7-59天对COVID-19相关住院的保护效果为55%(95%CI 42%-65%),≥60天为47%(95%CI 35%-57%);对COVID-19相关死亡的保护效果7-59天为71%(95%CI 46%-84%),≥60天为51%(95%CI 24%-69%);对COVID-19相关血栓栓塞事件为44%(95%CI 24%-59%)。

要点

  • ≥18岁透析终末期肾病患者接种2023-2024年度COVID-19疫苗对住院的保护效果7-59天为55%,≥60天为47%。
  • 对COVID-19相关死亡的保护效果7-59天为71%,≥60天为51%。
  • 对COVID-19相关血栓栓塞事件的保护效果为44%(95%CI 24%-59%)。

核心结论

  • 2023-2024年度COVID-19疫苗为终末期肾病成人提供针对COVID-19相关住院、死亡和血栓栓塞事件的保护。
  • 这些数据支持终末期肾病成人接种更新版COVID-19疫苗的推荐。

研究设计与样本

  • 回顾性队列研究,纳入≥18岁接受透析的终末期肾病医疗保险按服务收费受益人,使用医疗保险注册和理赔记录。
  • 随访自2023年9月17日开始,至COVID-19相关结局理赔、其他删失事件或随访结束中最早发生者为止。
  • 采用边际结构Cox模型估计疫苗效果([1-风险比]×100%),比较接种与未接种2023-2024年度COVID-19疫苗剂次的获益。

主要发现

  • 2023年9月17日至2024年4月13日期间,无其他免疫抑制条件的≥18岁终末期肾病患者中17,749/112,250(16%)接种了2023-2024年度COVID-19疫苗剂次,自接种起最大随访209天。
  • 随访期间记录6,539例就医COVID-19事件,包括3,605例COVID-19相关住院、789例COVID-19相关死亡和896例COVID-19相关血栓栓塞事件。
  • 对COVID-19相关住院的疫苗效果:接种后7-59天为55%(95%CI 42%-65%),≥60天为47%(95%CI 35%-57%)。
  • 对COVID-19相关死亡的疫苗效果:接种后7-59天为71%(95%CI 46%-84%),≥60天为51%(95%CI 24%-69%)。
  • 对COVID-19相关血栓栓塞事件的疫苗效果为44%(95%CI 24%-59%)。

临床怎么用

  • 作者认为这些数据支持终末期肾病成人接种更新版COVID-19疫苗的推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Persons with end stage kidney disease (ESKD) on dialysis are at high risk for severe COVID-19 disease. In September 2023, 2023-2024 COVID-19 vaccination was recommended in the United States for all persons aged ≥6 months. Due to possible immune dysfunction, advanced age, and high prevalence of additional underlying conditions, including immunocompromising conditions, among individuals with ESKD, reduced vaccine effectiveness (VE) is a concern. Understanding effectiveness of 2023-2024 COVID-19 vaccine among persons with ESKD can inform COVID-19 vaccine recommendations for this population. METHODS: A retrospective cohort investigation was conducted among Medicare fee-for-service beneficiaries aged ≥18 years with ESKD receiving dialysis using Medicare enrollment and claims records. Follow-up began on September 17, 2023, and continued until the earliest occurrence of claim for a COVID-19-associated outcome, other censoring event, or end of follow-up. A marginal structural Cox model was used to estimate VE (calculated as [1 - hazard ratio]*100 %), interpreted as the benefit of 2023-2024 COVID-19 vaccination compared with no 2023-2024 vaccine dose. VE was estimated by presence of additional immunocompromising conditions, age group, and time since vaccination. RESULTS: During September 17, 2023 - April 13, 2024, 17,749/112,250 (16 %) Medicare beneficiaries aged ≥18 years with ESKD without additional immunocompromising conditions received a 2023-2024 COVID-19 vaccine dose, with a maximum 209 days of follow-up since vaccination. During the follow-up period 6539 medically attended COVID-19 events, including 3605 COVID-19-associated hospitalizations, 789 COVID-19-associated deaths, and 896 COVID-19-associated thromboembolic events, were recorded. VE against COVID-19-associated hospitalization was 55 % (95 % confidence interval [CI]: 42 % - 65 %) at 7-59 days after vaccination and 47 % (95 % CI: 35 % - 57 %) at ≥60 days after vaccination. VE against COVID-19-associated death was 71 % (95 % CI: 46 % - 84 %) at 7-59 days after vaccination and 51 % (95 % CI: 24 % - 69 %) ≥60 days after vaccination. VE against COVID-19-associated thromboembolic events was 44 % (95 % CI, 24 %, 59 %). CONCLUSIONS: The 2023-2024 COVID-19 vaccines provided protection against COVID-19-associated hospitalization, death, and thromboembolic events among adults with ESKD. These data support the recommendation that adults with ESKD receive the updated COVID-19 vaccine.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Payne AB, Novosad S, Sung HM, et al. Effectiveness of 2023-2024 COVID-19 vaccines against COVID-19-associated hospitalizations among adults aged ≥18 years with end stage kidney disease - United States, September 2023-April 2024. Vaccine. 2025. PMID: 40184817. doi:10.1016/j.vaccine.2025.127010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。